Precision System Science Co., Ltd.
Stock Price Chart
2026/09/29 18:54 UpdatedPrice Trend
2026/09/29 18:54 UpdatedPrice & Trading Details
2026/09/29 18:54 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Major Holders
Updated 2026/09/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR Portfolio Developed World ex-US ETF
|
34.7K | 0.00% |
Dividend History
Updated 2026/09/27| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥2 | -60.0% |
| 2021 | ¥5 | -33.3% |
| 2014 | ¥8 | -34.8% |
| 2013 | ¥12 | +53.3% |
| 2010 | ¥8 | - |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥7,434M | ¥5,278M | ¥3,980M | ¥5,217M |
| Gross Profit | ¥2,487M | ¥1,350M | ¥950M | ¥1,584M |
| Operating Income | ¥152M | -¥1,112M | -¥956M | ¥201M |
| Pretax Income | ¥206M | -¥1,235M | -¥1,071M | ¥271M |
| Net Income | ¥45M | -¥1,324M | -¥1,121M | ¥395M |
| EPS | ¥1.64 | -¥47.93 | - | ¥14.42 |
| Operating Margin | 2.05% | -21.08% | -24.03% | 3.86% |
| Balance Sheet | ||||
| Total Assets | ¥11,410M | ¥9,762M | ¥6,397M | ¥5,854M |
| Total Equity | ¥6,512M | ¥5,222M | ¥4,143M | ¥4,090M |
| Total Liabilities | ¥4,898M | ¥4,539M | ¥2,254M | ¥1,764M |
| Cash | ¥2,764M | ¥2,446M | ¥1,915M | ¥1,366M |
| Interest-bearing Debt | ¥4,019M | ¥3,866M | ¥1,367M | ¥1,025M |
| Equity Ratio | 57.07% | 53.50% | 64.77% | 69.87% |
| D/E Ratio | 0.62 | 0.74 | 0.33 | 0.25 |
| Cash Flow | ||||
| Operating CF | ¥869M | -¥7M | -¥107M | ¥51M |
| Investing CF | -¥2,285M | -¥214M | ¥2,057M | -¥98M |
| Financing CF | ¥94M | -¥154M | -¥2,508M | ¥461M |
| Free CF | -¥1,380M | -¥162M | -¥131M | -¥51M |
| Efficiency | ||||
| ROE | 0.70% | -25.36% | -27.07% | 9.65% |
| ROA | 0.40% | -13.57% | -17.53% | 6.75% |
Latest IR Information
-
Notice of Changes in Corporate Officers
Announced changes to corporate officers. Mr. Ryoji Karinaga will move from Senior Managing Director to Director; his responsible divisions remain Reagent Manufacturing Division, New Business Promotion Department, and Life Science Business Division, with only the official title changed.
Read more -
Presentation Materials on Business Plan and Growth Potential
Explains the PSS platform business model centered on the company's nucleic acid extraction instruments. Proposes a policy to expand recurring revenue by combining ODM and own-brand sales centered on the magnetic-particle nucleic acid extraction technology "Magtration@". Describes the market outlook...
Read more -
Financial Results Briefing Materials for the Fiscal Year Ending June 2026
For the fiscal year ending June 2026, the company returns to profitability on a consolidated basis. The summary covers the actual results for the year ended June 2026, the outlook for the year ending June 2027, progress of the PSS...
Read more -
(Correction) Notice regarding partial correction of the Financial Summary (Consolidated) for the fiscal year ending June 2026
Partial correction to the Financial Summary for the fiscal year ending June 2026. The corrected components of the revenue mix are shown with underlining; the composition ratios and amounts for Equipment, Reagents & Consumables, Services & Others have been revised.
Read more -
Precision System Science Corporation 2026 June Term Financial Summary
Sales of 5,216 million yen (YoY +11.2%), operating income turned positive at 201 million yen, net income attributable to owners of the parent improved to 394 million yen. For the year ending June 2027, sales are expected to be 5,650...
Read more
Latest News (5 items)
Company Information
About
Precision System Science Co., Ltd., together with its subsidiaries, develops, manufactures, and sells automated systems and instruments, other physicochemical instruments, software, and other products in Japan, North America, Europe, and internationally. The company offers magLEAD 12gC LiNK, an automated nucleic acid extraction system. It also provides extraction reagents comprising MagDEA Dx SV, a prefilled reagent cartridge for magnetic bead-based nucleic acid extractions; MagDEA Dx MVII, a highly concentrated nucleic acid extraction reagent for viral nucleic acid extraction of cfNDA extraction; and MagDEA Dx SV RNA, a total RNA extraction reagent, as well as MagDEA Dx LV. In addition, the company offers fully automated PCR systems consisting of geneLEAD XII plus and geneLEAD VIII, which are fully automated sample-to-sample result instruments for molecular testing. Further, it provides research reagents, including LeeChip 45-uni, a lectin microarray for glycan profiling analysis; plastic consumables; and electronic equipment. The company's products are used for research and development, as well as for the in vitro diagnosis (IVD) testing market, including genetic and protein tests. Precision System Science Co., Ltd. was incorporated in 1985 and is headquartered in Matsudo, Japan.
